Evidence map›Paper›PMID 32325754›Full record

ArticleInternational journal of molecular sciences2020

Xun Zhou, Jamal Bouitbir, Matthias E Liechti, Stephan Krähenbühl, Riccardo V Mancuso

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. ExperimentalMolecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xun ZhouDivision of Clinical Pharmacology & Toxicology, University Hospital Basel, 4031 Basel, Switzerland.
Jamal BouitbirDivision of Clinical Pharmacology & Toxicology, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-4453-9457
Matthias E LiechtiDivision of Clinical Pharmacology & Toxicology, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-1765-9659
Stephan KrähenbühlDivision of Clinical Pharmacology & Toxicology, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0001-8347-4145
Riccardo V MancusoDivision of Clinical Pharmacology & Toxicology, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-4242-6096
University of Basel · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung SNF 31003A_156270
6 · The paper itself

Abstract

Halogenation of amphetamines and methcathinones has become a common method to obtain novel psychoactive substances (NPS) also called "legal highs". The

Indexed as

Adenosine TriphosphateAmphetamineAmphetaminesApoptosisCell DifferentiationCell Line, TumorElectron TransportHalogenationHumansInhibitory Concentration 50Membrane Potential, MitochondrialMethylaminesMitochondriaNeuroblastomaOxygen ConsumptionPropiophenones4-fluoroamphetamine4-fluoromethcathinoneAdenosine TriphosphateAmphetamineAmphetaminesclephedroneMethylaminesPropiophenonesReactive Oxygen SpeciesSuperoxidesamphetaminemethcathinonemitochondrianeurotoxicitypara-halogenation

Identifiers

PMID32325754
PMCPMC7215714
OpenAlexW3017295126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.